A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

被引：0

作者：

Crombie, Jennifer L. ^{[1
]}

Ryan, Christine E. ^{[2
]}

Ren, Yue ^{[2
]}

Tyekucheva, Svitlana ^{[3
]}

Carey, Celeste ^{[4
]}

Zou, Aaron ^{[4
]}

Normilus, Samantha ^{[4
]}

Montegaard, Josie ^{[4
]}

Soumerai, Jacob D. ^{[5
]}

Bhandari, Shruti ^{[6
]}

Arnason, Jon E. ^{[7
]}

Alencar, Alvaro J. ^{[8
]}

Kim, Austin I. ^{[9
]}

Parry, Erin M. ^{[2
]}

Armand, Philippe ^{[2
]}

Fisher, David C. ^{[2
]}

Brown, Jennifer R. ^{[10
]}

Davids, Matthew S. ^{[11
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[4] Dana Farber Canc Inst, Boston, MA USA

[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[6] Northern Light Canc Care, Dept Hematol & Oncol, Brewer, ME USA

[7] Beth Israel Deaconess Med Ctr, Boston, MA USA

[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Div Hematol, Miami Beach, FL USA

[9] Dana Farber Canc Inst, Dept Med Oncol, Newton Ctr, MA USA

[10] Dana Farber Canc Inst, Dept Med Oncol, Newton, MA USA

[11] Dana Farber Canc Inst Inc, Dept Med Oncol, Boston, MA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199234

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4628 / 4629

页数：2

共 50 条

[11] Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Danilov, Alexey V.
Lam, Vi
Bria, Thurlow
Spurgeon, Stephen E.
Park, Byung
Orand, Kirsten
Kittai, Adam S.
BLOOD, 2021, 138
[12] Phase I/II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL)
Tsimberidou, A. M.
Wierda, W. G.
Plunkett, W. K.
O'Brien, S.
Lerner, S.
Smith, S. C.
Kantarjian, H. M.
Keating, M. J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[13] Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Lavie, David
Ozcan, Muhit
Chaudhry, Arvind
Zhou, Xuan
Paydar, Ima
Farooqui, Mohammed Z. H.
Ghia, Paolo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S353 - S353
[14] A Systematic Literature Review of Utility Estimates for Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Yucel, E.
Hartley, L.
Bell, J.
Wolowacz, S.
Kamgar, F.
Hawe, E.
VALUE IN HEALTH, 2022, 25 (12) : S395 - S395
[15] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Barr, Paul M.
Ma, Shuo
Zent, Clive S.
Baran, Andrea M.
Bui, Andrew
Meacham, Philip J.
Morrison, Ashley
Holkovic, Kelsey
Liesveld, Jane L.
Mulford, Deborah A.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Friedberg, Jonathan W.
Hill, Brian T.
BLOOD, 2020, 136
[16] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 19 - 20
[17] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Barr, Paul M.
Hill, Brian T.
Ma, Shuo
Baran, Andrea M.
Bui, Andrew
Meacham, Philip J.
Morrison, Ashley
Liesveld, Jane L.
Mulford, Deborah A.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Friedberg, Jonathan W.
Zent, Clive S.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 9 - 10
[18] Distinct immune signatures in chronic lymphocytic leukemia (CLL) and Richter's syndrome (RS).
Wang, Yucai
Sinha, Sutapa
Dong, Haidong
Secreto, Charla
Call, Timothy
Parikh, Sameer Ashok
Leis, Jose Francisco
Rech, Karen
Feldman, Andew L.
Kenderian, Saad
Kay, Neil E.
Ansell, Stephen M.
He, Rong
Ding, Wei
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[19] COST-EFFECTIVENESS OF VENETOCLAX AND RITUXIMAB COMBINATION THERAPY VERSUS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) IN COLOMBIA
Chacon-Acevedo, K. R.
Gamboa, O.
Quitian Reyes, D.
VALUE IN HEALTH, 2020, 23 : S37 - S37
[20] Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Brown, Jennifer R.
Davids, Matthew S.
Chang, Julie
Ma, Shuo
Biondo, Juliana
Mobasher, Mehrdad
Mun, Yong
Mato, Anthony R.
BLOOD, 2018, 132

← 1 2 3 4 5 →